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ABSTRACT
Migraine and temporomandibular disorders (TMD) are prevalent, debilitating orofacial pain
conditions involving peripheral and central sensitization of the trigeminal system. The proinflammatory neuropeptide calcitonin gene-related peptide (CGRP), which is synthesized and
secreted from trigeminal ganglion neurons, is implicated in the underlying pathology of migraine
and TMD. Secreted CGRP modulates the excitability state of neurons and glial cells that express
CGRP receptors. Recent studies from our lab in preclinical models of migraine and TMD have
provided evidence that dietary supplementation with a proanthocyanin-enriched grape seed
extract (GSE) inhibits trigeminal pain signaling. The effect of GSE was blocked by an
antagonist of the GABAB receptor, which is expressed on primary trigeminal neurons. My study
aimed to investigate the cellular mechanisms by which GSE functions to modulate CGRP
expression using primary trigeminal ganglion cultures. The effect of GSE on CGRP secretion
from trigeminal neurons was determined by radioimmunoassay. To determine if the effects of
GSE involve modulation of CGRP expression or the GABAergic system, changes in the
expression of CGRP, GAD 65/67, GABAA receptor, and GABAB1 and GABAB2 receptor
subunits were investigated by immunocytochemistry. GSE significantly inhibited the basal level
of CGRP secretion but did not alter the neuronal expression of CGRP. GAD 65/67 expression
levels in neurons were increased in response to GSE incubation. No change in the neuronal
expression of GABAA was observed in response to GSE. GABAB1 expression in neurons,
satellite glial cells, and Schwann cells increased in response to GSE. GABAB2 expression was
elevated in satellite glia and Schwann cells. My findings support the notion that GSE inhibition
of basal CGRP secretion involves increased neuronal GAD 65/67 and GABAB receptor
expression. GSE repression of CGRP release in the ganglion coupled with increased GABAB1
and GABAB2 glial cell expression would suppress neuronal excitability and the development of
peripheral sensitization. In summary, I propose that GSE mediates neuroprotective effects that
support its potential as a nutraceutical therapeutic in the management of migraine and TMD.
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INTRODUCTION

Migraine and Temporomandibular Disorder
Migraine is a severe form of headache that causes intense orofacial pain and is the most
common neurological disease [14; 44]. Migraine attacks are characterized by an intense,
debilitating, throbbing pain in the head and face and a strong aversion to light (photophobia),
sounds (phonophobia), and odors. In almost a third of migraineurs, attacks can be accompanied
by an aura, which is usually some form of visual disturbance, as well as severe nausea that can
cause vomiting [50; 61]. The pain, which can last from 4 to 72 hours, is typically experienced on
one side of the person’s head but can be bilateral. Migraines occur in stages; it first begins with
a prodrome phase. This phase may consist of digestive issues, mood changes, fatigue, and neck
and shoulder stiffness [94]. Hours after the prodrome phase, the migraine attack happens. This
is the stage when the head pain and nausea are most pronounced. Once the pain and nausea
begin to wear off, the postdrome phase begins. In this stage, which can last for more than 24
hours, the person is typically very tired and may be confused. This condition is referred to as
brain fog. When people experience a migraine, they are not able to go to work or carry out
normal daily functions for at least a couple of days. This greatly impacts the quality of life of
migraineurs. Migraine is classified either as episodic or chronic based on the number of
headache days experienced each month with chronic migraineurs reporting more than 15
headache days per month. There are currently numerous pharmacological and alternative
therapeutic strategies to help prevent and abort migraine attacks [13]. Despite the recent
progress, many migraine sufferers report inadequate pain and symptom relief along with the
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experience of negative side effects. Hence, there remains a need to better understand migraine
pathology and develop safe and effective therapeutic strategies.
Based on patient surveys, a variety of environmental and internal triggers have been
identified that can initiate a migraine attack [9; 42; 50; 86]. Hormonal changes in women, stress,
excess caffeine, poor sleep quality, and a change in weather can all be triggers. Migraine is
estimated to affect roughly 18 percent of the global population. Women are 2-3 times more
likely than men to experience migraines. This sex difference is partly attributed to the hormonal
differences between the two sexes that promote underlying cellular and molecular differences.
Another risk factor for experiencing migraines is family history or one’s genetic background;
having a family member with migraines increases your likelihood of experiencing a migraine
during your lifetime [61]. Migraine is often comorbid with another prevalent orofacial pain
condition known as temporomandibular disorder or TMD [25; 40].
TMD is a group of medical conditions involving dysfunction of the temporomandibular
joint (TMJ) and/or associated muscles of mastication [89]. The TMJ is the only dually hinged
joint in the human body, and TMD pathology can involve inflammation and pain in one or both
joints. Following injury, the joint capsule can become inflamed. This leads to swelling, redness,
and tenderness near the joint. Depending on the severity of the injury and the body’s healing
response, an injury can lead to development of chronic pain in the facial region surrounding the
jaw and near the ear. TMD can make chewing food more difficult, more painful, and inhibit
proper jaw movement during normal activities such as speaking [71]. When a patient goes in for
diagnosis, the exact cause of TMD development is usually never determined. Injury to the jaw,
genetic predisposition, and teeth clenching and grinding caused by an unmanaged stress response
can contribute to the pathology associated with TMD [67; 88]. Treatment regimens for TMD
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include pain relief with over-the-counter anti-inflammatory medications, lifestyle modification to
avoid any triggers that aggravate the jaw, and surgery as a last resort [73]. Surgeries performed
to repair a damaged TMJ capsule do not always help the patient, and oftentimes can pose a risk
for causing further damage and long-term pain and disability. The prevalence of TMD is
reported as 5-12% in the U.S. population. Like migraine, TMD is two times more common in
women than in men [8; 67]. Both migraine and TMD are prevalent orofacial pain diseases
characterized by sensitization and activation of the primary afferent nerves within the trigeminal
ganglion [20; 80].

Trigeminal Ganglion
The trigeminal ganglion is the part of the peripheral nervous system responsible for
connecting the head and facial region to the central nervous system [46]. This collection of
nerve cells allows for transmission of sensory information, such as chemical, mechanical, and
thermal signals from peripheral tissues to the spinal cord and brain [83]. Humans have two
trigeminal ganglia, with one on each side of the body. They lie in a depression that is located
next to the temple, in front of the ears, and behind the eyes. The trigeminal ganglion has three
main nerve branches including the ophthalmic (V1), maxillary (V2), and mandibular (V3) [82;
84; 85]. Each branch conveys sensory signals from a different area of the face to the upper
spinal cord. The V1 branch provides sensory innervation to the upper facial region and the top
of the frontal area of the head. V2 provides innervation of the sinus/nasal region, and V3
innervates the jaw and lower facial region. V3 is considered a mixed nerve since it also provides
motor function for mastication.
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The trigeminal ganglion consists of primary afferent neurons, or neurons that convey
signals from the peripheral nervous system to the central nervous system [20; 79; 80]. This
includes Aδ fiber and C fiber neurons (Fig. 1). The cell body and processes of Aδ fiber neurons
are larger than those of C fiber neurons. The diameter of the cell body of Aδ fiber neurons
ranges between 35 and 50 µm, while the cell body diameter of C fiber neurons is typically
between 20 and 30 µm. Aδ fibers transmit the sensation of temperature as well as sharp or acute
pain. Since all Aδ fibers are myelinated, they are responsible for very fast neurotransmission
that functions to protect peripheral tissues from injury or damage. Aδ fiber neurons respond to
signals by releasing the excitatory neurotransmitter glutamate and other excitatory
neurotransmitters into the spinal cord to cause sensitization and activation of secondary neurons.
The secondary neurons carry the signal to the thalamus. Tertiary neurons will then transmit the
signal to the sensory cortex for higher level processing and initiating a proper behavioral
response. Neurotransmitters and neuropeptides released from Aδ fiber neurons can also cause
sensitization and activation of glial cells such as astrocytes, microglia, and oligodendrocytes [47;
51]. These glial cells function to modulate the signaling pathway within the central nervous
system.
The other major cell type is the C fiber neurons. C fiber neurons transmit pain,
temperature, and the sensation of itch from peripheral tissues to the spinal cord [83]. In contrast
to Aδ fibers, C fibers are unmyelinated. Therefore, C fibers transmit sensory information slowly
and are involved in the more sustained transmission of sensations such as chronic or burning
pain. C fiber neurons transmit pain signals via the release of neurotransmitters and
neuropeptides like substance P and calcitonin gene-related peptide (CGRP) to secondary neurons
[52]. These neuropeptides can also promote sensitization and activation of glial cells such as
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satellite glia and Schwann cells within the ganglion and astrocytes, microglia, and
oligodendrocytes in the spinal cord [28]. Sensitization and activation of Aδ and C fiber neurons
within the three branches of the trigeminal ganglion are implicated in prevalent orofacial pain
conditions including migraine and TMD [20]. Activation of these primary sensory neurons leads
to increased neuron-glia signaling and the subsequent development and maintenance of
peripheral sensitization within the trigeminal ganglion and central sensitization in the spinal cord
[6; 22; 52].
Peripheral sensitization of primary sensory neurons, which is implicated in migraine and
TMD pathology, is associated with a lower activation threshold to cause depolarization [28]. A
lower activation threshold means that less stimuli are required to cause activation of the neurons.
Development of peripheral sensitization is known to involve enhanced neuron-glial cell
communication via paracrine signaling and gap junctions to mediate an inflammatory response
[31; 46; 90]. In addition to the primary afferent neurons, two types of glial cells are present in
the trigeminal ganglion including satellite glial cells and Schwann cells (Fig. 1). The cell body
of glial cells are smaller than those of neurons. Their nuclei have an elongated shape, while
neuronal nuclei have a very spherical and round morphology. Satellite glial cells are more
abundant than Schwann cells in the ganglion. Satellite glial cells form a continuous layer
wrapping around the neuronal cell body that functions to provide nutrients and to modulate the
excitability state of the neurons [28]. A key protein expressed by satellite glial cells is the ion
channel protein Kir 4.1, which functions as an inwardly rectifying potassium channel to remove
extracellular potassium ions, and hence decrease neuronal excitability [98]. Together, the
neuronal cell body and satellite glial cells form what is referred to as a functional unit that
develops within the first few weeks after birth in rats [30]. These cells are capable of forming
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gap junctions, a type of communication where two cells connect their cytoplasm to share small
molecules such as glucose, amino acids, and ions [43]. The gap junctions allow for enhanced
direct communication by metabolically and electrically coupling neurons and satellite glial cells
during migraine and TMD pathology. Both types of glia, satellite glia and Schwann cells,
function as neuromodulators to regulate the excitability state of trigeminal neurons [62].
Within the ganglion, Schwann cells have two distinct populations, myelinating, and nonmyelinating Schwann cells [45; 62]. Myelin, which forms a sheath around nerve axons to allow
for fast electrical conductance, is essential for axons to be able to transmit signals 100 times
more quickly than unmyelinated fibers. Myelinating Schwann cells wrap around the axon of all
Aδ nerve fibers. They respond to physiological cues of the axon to determine the thickness and
length of the myelin sheath produced. Non-myelinating Schwann cells wrap around multiple C
nerve fibers, forming a Remak bundle. Non-myelinating Schwann cells are thought to play a
role in maintenance and nutrient delivery to the axon of trigeminal C fiber neurons.

Calcitonin Gene-Related Peptide
The most studied neuropeptide in the trigeminal ganglion is calcitonin gene-related
peptide or CGRP and is the primary target of the most effective anti-migraine drugs [27; 35; 66].
This 37 amino acid proinflammatory neuropeptide is abundant in both the peripheral and central
nervous systems [75; 76]. There are two different isoforms of CGRP, α-CGRP and β-CGRP
[74]. α-CGRP is the form expressed in Aδ and C fiber nociceptive neurons within the trigeminal
ganglion. β-CGRP is expressed in enteric neurons that regulate multiple cellular functions
within the gut. α-CGRP is the focus of my thesis project and will be referred to as CGRP in the
following text. The cellular effects of CGRP are mediated via activation of the CGRP receptor
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[7; 52]. The CGRP receptor is comprised of two main transmembrane proteins, receptor
activity-modifying protein (RAMP1) and calcitonin like-receptor (CLR). There are 3 RAMP
family proteins, but RAMP1 is primarily involved in CGRP signaling since RAMP1 has the
highest affinity for CGRP. A primary function of RAMP1 is to facilitate the movement of the
receptor complex to the surface of the cell, which controls when the CGRP ligand can bind and
allows for specificity. The functional CGRP receptor is formed when RAMP1 and CLR form a
complex. In addition to the two main proteins, the CGRP receptor is associated with two
proteins within the cytoplasm. These are the receptor coupling protein (RCP) and the α subunit
of the Gs protein, which is the CLR receptor subunit. Gs proteins are stimulatory guanine
nucleotide-binding proteins that act as a switch to initiate intracellular cell signaling. The α
subunit of the Gs protein is responsible for the transduction of the signal for the CGRP pathway.
The RCP protein is necessary for the Gsα subunit to properly transmit the signal. Once the Gsα
protein is activated, it binds and stimulates the enzyme adenylate cyclase [17]. Activation of
adenylate cyclase leads to a large increase in the intracellular level of the secondary messenger
cyclic AMP (cAMP) via a structural change of ATP. cAMP then activates the multifunctional
enzyme protein kinase A (PKA). PKA stimulates synthesis and release of nitric oxide,
cytokines, and other proinflammatory molecules from neurons and glial cells. The CGRP
receptor is expressed on neurons, satellite glial cells, and Schwann cells within the trigeminal
ganglion and secondary neurons, astrocytes, and microglia in the spinal cord [26; 52].
At normal physiological levels, CGRP regulates many cellular functions that may be
protective. However, elevated levels of CGRP are associated with migraine and TMD pathology
[7; 17]. Following the discovery of CGRP, it was quickly identified as the most potent
vasodilatory neuropeptide. CGRP is synthesized in the neuronal cell body where it is stored in
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dense-core vesicles in the cytosol and neuronal processes. CGRP secretion is stimulated by
activation of the neurons within the trigeminal ganglion. When released perivascularly, it
promotes neurogenic inflammation, which is characterized by blood vessel dilation, plasma
protein extravasation, degranulation of mast cells, and recruitment of immune cells [5]. This
type of inflammatory response can serve a protective function by preventing ischemic events,
minimizing tissue damage, promoting tissue repair, and restoring homeostasis. CGRP also
functions as a pain signaling molecule to mediate sensitization and activation of primary
neurons, secondary neurons, and glial cells [28]. When sensitized, the neurons in the peripheral
nervous system have a higher excitability state, which correlates to a lower activation threshold.
Thus, a smaller change in membrane potential is required to initiate a cellular response and
facilitate pain signaling. The neuronal membrane potential is referring to the difference in
electrical charge within the cell compared to the environment outside of the cell. The cytoplasm
of neurons at rest is negatively charged to a potential of about -60 to -75 millivolts. A higher
excitability state would mean that the potential of the cell is still negative, but to a lesser degree.
Hence, it is easier for a stimulus to open a ligand-gated positive ion channel and cause
depolarization of the cell, and subsequent release of CGRP and other neurotransmitters.
CGRP not only initiates peripheral sensitization, but it perpetuates this hyperexcitable
state by creating an inflammatory feedback loop [17; 97]. CGRP acts as an autocrine signal to
stimulate the synthesis and secretion of more CGRP by binding to the CGRP receptor on the
trigeminal neuron that originally released it. It also acts as a paracrine signal to stimulate
proinflammatory cytokine release, such as tumor necrosis factor-α (TNF-α), from satellite glial
cells. Nearby release of TNF-α stimulates further CGRP transcription and secretion [10; 36].
Additionally, CGRP stimulates synthesis of nitric oxide release from neurons as well as both
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Schwann and satellite glial cells [58]. Nitric oxide is another potent vasodilator and functions in
collaboration with CGRP to prolong the inflammatory response in response to trigeminal nerve
activation [4]. The increase in neuron-glial cell communication involving CGRP, cytokines, and
nitric oxide mediates peripheral sensitization and is implicated in chronic orofacial pain
conditions [28].
In the case of migraine, a chronic orofacial pain disease, release of CGRP from the
trigeminal ganglion results in inflammation in the meninges of the brain [44]. This inflammation
is what causes the severe pain associated with a migraine attack. Given that elevated CGRP
levels in cerebral spinal fluid, saliva, and serum have been reported during a migraine attack, it is
not surprising that this neuropeptide has become a key target of migraine therapeutics including
drugs such as the triptans and gepants, onabotulinumtoxinA, and biologics such as CGRP
monoclonal antibodies that are directed against the peptide or its receptor [72]. Inhibition of
CGRP release and prevention of CGRP receptor activation in neurons and glia in the trigeminal
ganglion and spinal cord has helped migraine patients manage their pain and decrease associated
symptoms. Based on published work from our laboratory, other therapeutic strategies such as
inclusion of dietary supplements that function as nutraceuticals have been shown to be effective
in inhibiting pain signaling and inflammation and inhibit CGRP expression in preclinical models
of migraine and TMD [1; 15; 16; 18; 21; 24; 48; 101].

Grape Seed Extract
Grapes, grape leaves, sap, and grape seeds have been used in ancient medicine for a
variety of health benefits [59; 65]. The grape seed extract (GSE, Healthy Origins MegaNatural®
BP-Grape Seed Extract) used in our prior published studies [18; 21; 24; 101] and my thesis

9

research is a commercially available extract made from both red and white California grape
varieties. This extract is enriched in polyphenols. Polyphenols are a large, diverse class of
secondary plant compounds known to protect against inflammation and oxidative stress [2]. A
major source of the grape’s polyphenolic content is found in the seeds. One of the main classes
of polyphenols found in GSE is proanthocyanins. These polyphenols are powerful antioxidants
and as such provide a broad range of benefits by reducing oxidative stress. Previous findings
from our laboratory have provided evidence that the addition of GSE as a daily supplement to the
drinking water of Sprague-Dawley rats inhibits the development of central sensitization within
the spinal cord and peripheral sensitization in the trigeminal ganglion by modulating the
excitability state of neurons and glia [18; 21; 24; 101]. Importantly, the inhibitory effect of GSE
involves repression of basal CGRP expression in the spinal cord. Elevated levels of CGRP in the
spinal cord are known to promote both central and peripheral sensitization of trigeminal
nociceptive neurons [54]. In summary, there are multiple lines of evidence to support the notion
that GSE functions in a neuroprotective capacity via modulation of neuronal CGRP expression.
This nutraceutical offers a non-pharmacological therapeutic modality for migraine and TMD and
possibly other chronic inflammatory pain conditions.
Supplements, like GSE, are considered a nutraceutical rather than a pharmaceutical.
Nutraceuticals are natural bioactive compounds that show physiological benefit to human health.
They can be used not only as treatment for a disease, but as a preventative before pathology
begins. In a society where our approach to human health is primarily focused on treatment after
pathology has occurred, identification of modalities that prevent the development and
progression of disease remains a much-needed area of emphasis. Pharmaceuticals typically are
advantageous in treating a specific disease by inhibiting the molecule that is implicated in the
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underlying pathology, such as CGRP in migraine. In contrast, nutraceuticals enhance the
expression of proteins and pathways that suppress inflammation and pain signaling, and function
to restore and maintain healthy physiological systems. Another major difference is the fact that
recommended therapeutic doses of pharmaceuticals can be associated with negative side effects.
Nutraceuticals usually do not cause any significant side effects. They are consumed at lower
levels in one’s diet on a regular basis and function not as abortive therapies, but as preventative
therapeutics. Combining nutraceuticals with pharmaceuticals could offer an additive or
synergistic therapeutic benefit and hence function as adjunctive therapies. Taking a
pharmaceutical in addition to a nutraceutical may allow the pharmaceutical to be taken at a lower
dose, perhaps decreasing the burden of side effects, and increasing its efficacy.
Based on our findings and supported by the National Institutes of Health Complementary
and Integrative Health website, GSE should be considered in the management of pain associated
with migraine, TMD, and other chronic orofacial pain conditions. In support of this notion,
dietary supplementation with GSE was found to inhibit nociception and latent sensitization in
preclinical models of chronic TMD and episodic migraine [18; 21; 24; 101]. Our lab has
previously documented how GSE functions to prevent central sensitization, but there is a gap in
knowledge about how GSE is functioning in the peripheral system at the level of the trigeminal
ganglion. Polyphenols can cross the blood brain barrier [39], making them capable of exerting
effects in both the central nervous system and the peripheral nervous system. In the central
nervous system, polyphenol-enriched GSE effects involve activation of the serotonin receptor 5HT, the endocannabinoid receptors CB1 and CB2, and the GABAB receptor to modulate
descending pain [21; 24; 101]. Other widely used pharmaceutical pain relievers, such as
morphine and opioids, also work through enhancing the inhibitory descending pain modulation
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pathway to prevent pain signaling. Elucidating the cellular mechanisms of how GSE targets the
peripheral nervous system in the trigeminal ganglion to modulate descending pain pathways
mediated by CGRP was the focus of my thesis.

GABAergic System
Results from our preclinical studies have demonstrated that the inhibitory properties of
GSE involve in part, activation of gamma-aminobutyric acid (GABA) receptors [21] within the
spinal cord. GABA is a key inhibitory neurotransmitter in the brain and spinal cord of mammals
[38]. Lack of GABA in the nervous system can lead to psychological diseases such as anxiety
and depression[37; 77]; these conditions are often comorbid with CGRP-implicated orofacial
pain diseases like TMD and migraine[64; 87]. Although glutamate is the structural precursor of
GABA, they exert opposing effects on nerve cells. Glutamate is the most abundant excitatory
neurotransmitter in the brain and spinal cord, while GABA is the most abundant inhibitory
neurotransmitter. Hence, while glutamate facilitates neuronal activation and pain signal
transduction, GABA inhibits neurons from being able to relay inflammatory and painful
information. Glutamate and CGRP, which are implicated in migraine pathology, are coexpressed in trigeminal ganglion neurons, and are simultaneously released into the spinal cord
following activation by peripheral stimuli [81; 102]. CGRP potentiates the excitatory effects of
glutamate by binding to secondary neurons, causing the glutamate receptor N-methyl-Daspartate (NMDA) to be brought to the cell surface. The upregulation of NMDA receptors
induced by CGRP facilitates nociceptive signaling to the thalamus via the ascending pain
pathway. GABA counters the effects of glutamate by reducing the excitability state of neurons
and therefore blocking their activation via the descending pain modulation pathway [70]. If
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neurons are not able to become activated, they will not transmit a signal to other neurons. The
inhibitory effect of GABA is mediated via activation of GABA receptors expressed on primary
and secondary neurons and glial cells in the trigeminal ganglion and spinal cord. For example,
the reduced excitability state of primary and secondary trigeminal neurons caused by GABA is
likely to involve the opening of a chloride ion channel in the cell membrane that makes the
membrane in the cell more negative, which prevents generation of an action potential [55]. This
cellular response opposes the effect of ligands that increase excitability, such as CGRP. In this
way, GABA is not only responsible for promoting an anti-anxiety effect but can also function to
inhibit pain signaling pathways [38].
GABA is synthesized in the cell body cytoplasm of a presynaptic neuron [100].
Glutamate decarboxylase (GAD) is the enzyme exclusively responsible for GABA synthesis. It
functions to catalyze a decarboxylation reaction of glutamate to produce GABA and carbon
dioxide. There are two isoforms of GAD: GAD 65 and GAD 67. GAD 65 is localized to the
plasma membrane of GABAergic neurons, while GAD 67 is found primarily in the cytoplasm of
neurons. Both isoforms are abundantly expressed in trigeminal ganglion neurons [99].
Synthesized GABA is stored in synaptic vesicles just below the plasma membrane of a neuron
until vesicular release is initiated in response to a stimulatory signal [3; 38]. To facilitate
exocytosis from the cell, the GABA-containing vesicle will align and fuse with the plasma
membrane. This allows for GABA to be released outside of the cell into the synaptic cleft or
extracellular matrix of the neuron. GABA can then bind to GABA receptors on another neuron
or glial cell, or be taken up by transport proteins, and function to decrease neuronal excitability.
The GABA ligand can bind to 2 different GABA receptors: GABAA and GABAB [3;
38]. GABAA is an ionotropic or ligand-gated ion channel receptor and functions to allow an
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influx of negatively charged chloride ions into the intracellular space when the GABA ligand is
bound [63]. This increase in negatively charged ions lowers the excitability state of the cell by
inhibiting generation of an action potential and the release of neurotransmitters and
neuropeptides, as well as other pro-inflammatory molecules. GABAA consists of 5 subunits
with two alpha groups, two beta groups, and one gamma group. Within the trigeminal ganglion,
the GABAA receptor is expressed in both types of neurons [100].
GABAB, a G-protein coupled receptor comprised of the subunits GABAB1 and
GABAB2 [53], is expressed on the cell surface of neurons, satellite glia [92], and Schwann cells
[60]. Due to the nature of G-protein coupled receptors, activation of GABAB receptors may
function as a preventative therapeutic while activation of GABAA receptors are likely to
function as an abortive treatment [78]. Towards this end, the therapeutic benefit of non-invasive
vagus nerve stimulation in aborting migraine was shown to involve activation of GABAA
receptors within the spinal cord of rats [23]. Both subunits, GABAB1 and GABAB2, are
structurally similar; they consist of an extracellular domain called the Venus flytrap domain
(VFT), a 7 transmembrane domain called the heptahelical transmembrane domain (7TM), and a
C-terminal tail [41]. The tails of the GABAB1 and GABAB2 subunits coil together within the
intracellular space of the cell. The GABAB receptor only functions as a heterodimer; the two
subunits cannot function without the other. Without GABAB2, GABAB1 is restricted to the
endoplasmic reticulum and thus would not allow GABA to bind. GABAB2 allows for the
translocation of GABAB1 to the cell surface and stabilization of the receptor. Because of this,
GABAB2 can alter the binding affinity of GABA on the B1 receptor. The VFT domain in the
B1 subunit is where the GABA ligand binds. This binding activates B2 to couple to an
inhibitory Gi/o protein. This G protein will dissociate into Gα and Gβγ. The Gα subunit inhibits
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the activity of the signal transduction enzyme adenylate cyclase, which is positively regulated by
CGRP. The inhibition of this enzyme activity leads to a reduction in cyclic AMP (cAMP) levels
within the cell, inhibiting signal transmission, secretion, and decreasing excitability of the
neuron. The Gβγ subunit activates inwardly rectifying K+ (GIRK) channels, a subclass of the
Kir family of channels, and inhibits voltage-gated calcium channels within neurons. Activation
of GIRK channels results in positively charged potassium ions leaving the cell and decreases the
neuronal membrane potential [11; 69; 93]. Inhibiting calcium channels blocks positively
charged calcium ions from entering the cell, which is required for depolarization and generation
of the action potential within a neuron.
Activation of the GABAB receptor within satellite glial cells causes stimulation of Kir
channels [92]. Kir channels function to transport extracellular potassium across the plasma
membrane into the cytoplasm to help maintain homeostasis. Dysfunction of this receptor is
associated with neurons becoming hyperpolarized and hyperresponsive to external stimuli [98].
Together, these GABA receptor-mediated mechanisms lower the excitability state of a neuron
and inhibit release of neurotransmitters and other signaling molecules in a neuroprotective
manner. In addition to their inhibition of neuronal excitability, GABA receptors on satellite glia
and Schwann cells function to decrease the excitability state of these cells, and thus disrupt the
neuron-glia inflammatory loop and suppress the development and maintenance of peripheral
sensitization.

Goal of the Study
In previous studies, we have shown that inclusion of GSE as a dietary supplement in the
drinking water of rats inhibited trigeminal nociception in preclinical models of chronic TMD and
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migraine [21; 24; 101]. The anti-nociceptive effect of GSE was blocked by injecting GABAB
receptor and 5-HT3/7 receptor antagonists in the upper spinal cord/brainstem. However,
administration of GABAA antagonists centrally did not block the inhibitory effects of GSE. In a
more recent study, GSE was shown to also function via activation of the endocannabinoid
system, which is important in facilitating descending pain modulation within the central nervous
system. Although our research has shown that GSE can modulate pain signaling and the
development of central sensitization in the spinal cord, it is not thoroughly understood how GSE
modulates the activity of neurons and glial cells within the trigeminal ganglion that mediate
peripheral sensitization.
In my thesis study, I wanted to investigate the cellular mechanisms by which the
proanthocyanin-enriched Healthy Origins MegaNatural® BP-Grape Seed Extract modulates
neuron and glial cell function using primary trigeminal ganglion cultures. Specifically, I wanted
to investigate GSE’s effect on CGRP secretion and peptide expression in trigeminal neurons.
Additionally, I wanted to explore GSE’s possible mechanism of action through the GABAergic
system by determining GAD 65, GAD 67, and GABA receptor expression using
immunocytochemistry. The main goal of my study was to test the hypothesis that GSE
suppresses basal CGRP secretion via upregulation of the GABA receptors on trigeminal neurons
and glial cells. I predicted that upregulation of GABA receptor expression in glial cells could
play a critical role in inhibition of the continuation of peripheral sensitization mediated by
increased CGRP-mediated neuron-glia communication. Results from my study will provide
novel insights into the mechanisms of how GSE polyphenolic compounds modulation of GABA
receptors could be useful as an adjunctive or alternative strategy for managing the pain and
inflammation associated with chronic orofacial pain diseases.
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V1

V2

V3

50µm

1000 μm

Fig. 1. Morphology of Trigeminal Ganglion. A representative image of 14 µm-thick section
of the trigeminal ganglion stained with DAPI and the 3 branches labeled (left). A 400x image
of functional units in a trigeminal ganglion with solid diagonal arrow pointing to the nucleus
of a satellite glia cell, hollow diagonal arrow pointing to a Schwann cell, solid horizontal
arrow pointing to an Aδ fiber neuron, and a hollow horizontal arrow pointing to a C fiber
neuron (middle). Kir 4.1 staining of satellite glial cells (right).
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METHODS

Animals
Animal protocols were approved by the Institutional Animal Care and Use Committee at
Missouri State University (IACUC protocol: 2020-06, see Appendix) and conducted in
accordance with the guidelines of the National Institutes of Health. Adult pregnant female
Sprague-Dawley rats were purchased from Missouri State University’s internal breeding colonies
at the Jordan Valley Innovation Center (Springfield, MO). Animals were housed in clean, plastic
cages with unlimited access to food and water. The holding room was kept at a constant
temperature of 22-24oC, with a 12-hour light/dark cycle. Three to five-day-old neonatal pups
were used to establish trigeminal ganglion cultures.

Establishment of Primary Trigeminal Ganglion Cultures
Primary cultures of trigeminal ganglia were established based on our previously
published protocols [1; 10; 32; 34; 96]. Briefly, trigeminal ganglia obtained following
decapitation of 3-5-day-old male and female neonatal Sprague-Dawley rats were placed in ice
cold Leibovitz (L-15, Sigma-Aldrich) plating media immediately following dissection. Once the
tissue had settled, media was poured off and replaced with L-15 media containing 10 mg/mL
Dispase II (Sigma-Aldrich) and 1 unit/µL RQ1 RNase-free DNase (Promega, Madison, WI).
Ganglia and media were divided into two 15 mL tubes and rotated at 15 RPM in a 37oC
incubator for 30 minutes. Tissues were observed for a noticeably feathery appearance after
rotation, which was indicative of tissue digestion. Tubes were then centrifuged at 500 RPM for 2
minutes and the supernatant was poured off. Tissues were resuspended in 5 mL of L-15 plating
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media. Tissues were dissociated by vigorous mechanical titration while carefully avoiding
introduction of air into the media. Once the larger connective tissue had settled, the cloudy cellcontaining media was removed and placed into a clean 15 mL tube. Media was centrifuged at
1300 RPM for 3 minutes to pellet neurons and glia. Isolated cells were resuspended in 37oC L15 medium containing 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA), 50 mM
glucose (Sigma-Aldrich), 250 mM ascorbic acid (Sigma-Aldrich), 8 mM glutathione (SigmaAldrich), 2 mM glutamine (Sigma-Aldrich), and 10 ng/mL mouse 2.5 S nerve growth factor
(Alomone Laboratories, Jerusalem, Israel). An antibiotic mixture of penicillin (100 units/mL)
and streptomycin (100 µg/mL, Sigma-Aldrich) in addition to the antimycotic amphotericin B
(2.5 mg/mL, Sigma-Aldrich) was added to the supplemented L15 media, which will be referred
to as TG complete medium.
For immunocytochemistry studies, cells isolated from 3 trigeminal ganglia were plated on
Poly-D-Lysine coated glass coverslips (Electron Microscopy Sciences, Hatfield, PA) in a 24well plate (Corning Incorporated-Life Sciences, Durham, NC) and incubated at 37oC. For the
secretion studies, cells isolated from 30 trigeminal ganglia were plated directly onto a 24-well
plate in 250 µL of media and incubated at 37oC. For the toxicity studies, cells isolated from 12
trigeminal ganglia were plated directly onto a 96-well plate in 175 µL of media and incubated at
37oC. Cells for immunocytochemistry and toxicity were incubated with a 1:10,000 dilution of a
5 mg/mL stock solution (final concentration of 500 ng/mL) of MegaNatural®-BP grape seed
extract (GSE, Healthy Origins, Pittsburgh, PA) prepared in cell water (BioWhittaker,
Walkersville, MD) the day after dissection and plating.
Cultures were left to grow overnight after GSE was added. All cultures used for
secretion, immunostaining, and toxicity studies were left to grow for a total of 2 days at 37oC
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before processing the cell cultures for further analysis. All coverslips for immunostaining were
fixed on day 3 using 4% paraformaldehyde (Sigma-Aldrich) and stored at 4oC. Following
fixation, cells for immunocytochemistry were imaged at 200x on a Motic AE31 inverted light
microscope with a Leica EC3 imager.

Testing Effect of GSE on Cell Viability
Following trigeminal ganglion culture setup and addition of a 1:1000 dilution of a 500
ng/mL GSE stock solution, viability of primary cultures after overnight incubation with GSE was
evaluated in triplicate using a CellTiter 96® AQueous One Solution Cell Proliferation Assay
(Promega) according to manufacturer’s instructions. DMSO (10%) was used as a control.
Briefly, 20 µL of CellTiter 96® Reagent was added to each well and incubated for 4 hours at
37oC. After incubation, the absorbance was measured at 490 nm using a plate reader.
Background absorbance was subtracted from signal and average values reported as absorbance at
490 nm.

GSE Regulation of CGRP Secretion
Primary cultures maintained in a 24-well tissue culture treated plate for 2 days were
rinsed with 250 µL of phosphate-buffered saline (PBS, Sigma-Aldrich) before 250 µL of fresh
HEPES-buffered saline (HBS: 22.5 mM HEPES, 135 mM NaCl, 3.5mM KCl, 1mM MgCl2, 2.5
mM CaCl2, 3.3 mM glucose, and 0.1% bovine serum albumin, pH 7.4) was added. Cells with
fresh prewarmed HBS were left to incubate at 37o C for 1 hour before media was collected into a
sterile 1.7 mL tube and labeled as “basal” secretion sample. Fresh prewarmed HBS (250 µL)
was added to each of the wells. Some cells remained untreated (naïve), while other cells were
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incubated for 60 minutes at 37oC with a final GSE concentration of 0.5 ng/µL. After 1 hour,
media was collected into sterile 1.7 mL tubes labeled as “final” secretion samples. Cells
remaining in the wells were rinsed with PBS twice before being scraped and collected into sterile
1.7 mL tubes labeled as “cell pellet” and later used for protein quantification.
The amount of secreted CGRP before and after GSE incubation was measured using a
radioimmunoassay specific for CGRP (Phoenix Pharmaceuticals, Inc., Burlingame, CA). This
assay was designed to detect levels of a specific peptide, rat CGRP, via competitive binding. An
antibody specific to CGRP is added to the samples in a limited quantity.

125

I-CGRP, a

radioactive synthetic version of CGRP, competes with the CGRP secreted from the trigeminal
primary cultures into the media. A larger quantity of secreted CGRP competes for the
radioactive CGRP’s binding ability, thus producing a lower radiation measurement. A standard
curve was generated that allows for quantification in the pg range of CGRP present in the
samples. Radioactive counts were normalized to protein concentration, which was used to
control for the number of plated cells per well. Total protein levels were determined using a
standard Bradford protein quantification assay with absorbance measured on a Spectra Max plus
384 plate reader. Briefly, a standard protein curve ranging from 0 µg/µL to 3.5 µg/µL was made
using bovine serum albumin (Sigma-Aldrich). Colorimetric Bradford reagent (Bio-Rad
Laboratories, Inc., Hercules, CA) was added to all wells, and the absorbance value at 595 nm
corresponds to protein abundance. The exact concentration in mg/mL is calculated based on the
standard curve. Average means of CGRP secretion from naïve and GSE incubated samples from
6 independent experiments performed in duplicate were determined and reported as average fold
change ± SEM relative to the average mean for naïve cultures, whose mean was set equal to one.
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GSE Modulation of Protein Expression by Immunocytochemistry
Immunocytochemistry was performed to investigate changes in protein expression levels
of naïve and GSE incubated primary trigeminal ganglion cultures. Primary cultures were
incubated with a 0.5 ng/µl GSE solution. Primary cultures established as described in a prior
section were treated with 5% donkey serum (Jackson ImmunoResearch Laboratories, West
Grove, PA) + 0.1% Triton solution (Sigma-Aldrich) for 20 minutes to block non-specific
antibody binding and permeabilize the cells. After rinsing with PBS three times, cells were
incubated at room temperature with primary antibody diluted in 5% donkey serum for three
hours (Table 1). After primary incubation, cells were rinsed with Tween 80 solution (Fisher
Scientific, Waltham, MA) two times followed by a rinse with PBS three times before being
incubated with Alexa-Fluor conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories). All secondary antibodies were prepared at a 1:200 dilution in 5% donkey serum
and incubated for one hour at room temperature while being protected from light. At the end of
secondary incubation, cells were rinsed with Tween twice and PBS three times. Coverslips from
the different experimental conditions were placed onto a double-frosted Fisher Scientific glass
microscope slide and mounted using 70 µL of Vectashield anti-fade medium containing the
nuclear fluorescent dye 4’,6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame,
CA). Slides were covered with a glass coverslip (Fisher Scientific) and secured with a clear coat
of nail polish (L.A Colors, Ontario, CA).
All slides were imaged using a Zeiss Axiocam mRm camera (Carl Zeiss, Thornwood,
NY) mounted on a Zeiss Imager Z1 fluorescent microscope within one week of staining and
were stored at 4o C. A minimum of three 200x images were taken of each coverslip. Zen 2
software (Carl Zeiss) was used to adjust the image backgrounds to match the nonspecific
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intensities. ImageJ software was used to analyze the immunostaining intensity. Intensity of the
signal when set to the FITC green channel was measured by making a rectangle around each cell
type of interest present in the image and subtracting the average background. Average means of
the fluorescent intensities for each protein of interest in neurons and glial cells were determined
and reported as average fold change ± SEM relative to the naïve average, which was set to one.
Each condition was repeated in triplicate in a minimum of 6 independent experiments.

Statistical Analysis
The following statistical analysis was performed for both immunocytochemistry and
secretion data using SPSS Statistics Software version 24 (IBM, North Castle, NY). A ShapiroWilk test was used to evaluate normality of data distribution. For all data that was found to be
normally distributed, a parametric independent t-test was performed. Levene’s test was used to
determine equal variances assumed. Independent t-tests were used to evaluate differences
between naïve and GSE incubated conditions. For data that was not normally distributed, a
nonparametric Mann Whitney U test was performed to determine differences between naïve and
GSE incubated conditions. Data were considered significant if p < 0.05.
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Table 1. Summary of Antibodies Used for Immunocytochemistry
Protein

Company; Catalog Number

Dilution

Incubation

CGRP

Abcam; Ab36001

1:2000

3 hr, room temp

β-tubulin

Abcam; Ab7751

1:5000

3 hr, room temp

GAD 65/67

Abcam; Ab11070

1:1000

3 hr, room temp

GABAA

Abcam; Ab72446

1:2000

3 hr, room temp

GABAB1

Abcam; Ab55051

1:2000

3 hr, room temp

GABAB2

Abcam Ab75838

1:2000

3 hr, room temp

1:200

1 hr, room temp

1:200

1 hr, room temp

Alexa-Fluor 488

Alexa-Fluor 647

JacksonImmuno Research;
711-545-152
JacksonImmuno Research;
705-605-147

24

RESULTS

Primary Culture Cell Types Mimic In Vivo Trigeminal Ganglion
Primary rat trigeminal ganglia cultures were used to study the effects of GSE on CGRP
secretion and GABAergic-related protein staining. To confirm that cell culture populations
resembled tissue cell composition, a fluorescent 4′,6-diamidino-2-phenylindole (DAPI) stain was
used to visualize the nucleus of all cells. The same 4 cell types (Schwann cells, satellite glial
cells, Aδ fiber neurons, and C fiber neurons) were found in whole trigeminal ganglia (Fig. 1) and
my established primary cultures of trigeminal ganglia (Fig. 2). Neurons were identified using a
DAPI stain and a light microscopy image based on their round nucleus with a size between 25
and 50 µm. Two types of neurons, Aδ and C fiber were differentiated based on nuclear size. Aδ
are larger than C fibers. Any neuronal cell body larger than 35 µm was considered an Aδ fiber
neuron, while any neuronal cell body smaller than 35 µm was considered a C fiber neuron.
Satellite glia were identified based on their small, more rounded nucleus. Schwann cells were
identified based on their elongated nucleus and bipolar process morphology. In culture, neurons
were present as approximately 14% (352 cells) of the total cell population. Aδ neurons made up
2% (48 cells) and C fiber neurons made up 12% (291 cells) of total cells. Glial cells made up
approximately 86% (2,126 cells) of the total cell population. Satellite glia cells and Schwann
cells made up 59% (1,452 cells) and 27% (674 cells) of cell populations, respectively (n = 24).
To further verify that primary cultures mimic the in situ trigeminal ganglion tissue, the
protein biomarkers calcitonin gene-related peptide (CGRP) and β-tubulin were detected using
immunocytochemistry (Fig. 3, n = 6). β-tubulin, which is a subunit of the cytoskeletal
microtubules and is localized in the cell bodies and processes, was used to show that cultured
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neurons retained a neuronal phenotype. β-tubulin was expressed in all neurons and neuronal
processes present in my cultures. CGRP, the proinflammatory neuropeptide of interest in this
study, was expressed abundantly in a subset of neurons and neuronal processes in cultures.
Costaining of β-tubulin and CGRP revealed that only a subset of Aδ and C fiber neurons stained
positively for CGRP. These data demonstrate neuronal expression of CGRP in less than half of
the total neurons, which is similar to the level observed in trigeminal ganglion [57].

Characterization of Healthy Origins MegaNatural® BP-Grape Seed Extract
To ensure that overnight incubation with GSE was not causing toxic effects, cultured
cells were incubated with GSE for 24 hours and cell viability was measured. Cell viability was
unaffected with GSE incubation compared to an untreated naïve control but was greatly reduced
by incubation with 10% DMSO (Table 2).

Effects of Grape Seed Extract on Basal CGRP Secretion
To determine if GSE could inhibit basal, or unstimulated, secretion of CGRP from
trigeminal ganglion neurons, cultures were incubated in HBS containing 2.5 µl of a 500 ng/mL
GSE solution, resulting in a final concentration of 0.5 ng/l (1.25 ng/well). As seen in Figure 4,
GSE incubation for 60 minutes caused a significant decrease in basal CGRP secretion (124.6 ±
48.2 pg, p = 0.025, n = 6) when compared to the baseline level of CGRP (389.6 ± 83.8 pg). The
level of CGRP in the HBS obtained from baseline and final naïve samples was measured as a
control to ensure that the 60-minute incubation time and a full change of HBS did not
significantly affect CGRP secretion. Naïve untreated cultures showed no difference between
baseline and final CGRP secretion levels, with basal measurements being 248.3 ± 73.6 pg, and
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final measurements being 221.6 pg ± 89.2 pg. Baseline CGRP secretion levels in wells prior to
GSE incubation were measured in pg/mL of HBS normalized to protein concentration to ensure
that the amount of baseline CGRP secretion was similar between the GSE incubated cultures and
naïve cultures. The assumption is that the protein value directly correlates with the number of
cells in each well. Although the average baseline levels of CGRP in GSE incubated wells were
slightly higher than naive baseline levels, the difference was not statistically significant between
these conditions. Since the concentration of GSE used for the secretion experiments did not
cause a change in cell viability following overnight incubation (Table 2), it is unlikely that the
decrease in CGRP secretion was due to cell toxicity. Taken together, these data provide
evidence that the repression of basal CGRP secretion was due to the 60-minute incubation of
cultures with GSE.

CGRP
To determine if GSE was causing a corresponding decrease in the expression of CGRP in
neuronal cells, trigeminal cultures were immunostained with antibodies against CGRP and
staining intensity measurements compared with naive levels (Fig. 5). In cultured trigeminal
ganglia, CGRP was detected only in neurons and their associated neuronal processes. Not all
neurons were positive for CGRP expression with less than half of neurons expressing CGRP at
higher levels and a small percentage of the population expressing detectable, but low levels of
CGRP. The relative intensity of CGRP staining was not altered with overnight GSE incubation
(101.1 ± 3.9, p = 0.459, n = 6) when compared to naïve conditions (96.0 ± 5.2). Based on a
summary of the average relative fold change ± SEM in CGRP staining intensity of GSE
incubated compared to naïve condition, GSE did not repress basal expression of CGRP.
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GAD 65/67
Immunocytochemistry was utilized to investigate changes in expression of GAD 65 and
GAD 67, the enzymes responsible for GABA synthesis, in response to GSE incubation (Fig. 6).
In cultured trigeminal ganglia, GAD 65/67 was detected abundantly in both Aδ and C fiber
neuronal cell bodies. The relative intensity of GAD 65/67 staining was significantly increased in
neurons with overnight GSE incubation (48.1 ± 3.2, p = 0.033, n = 9) compared to naïve
conditions (38.8 ± 2.4). A summary of the average relative staining intensity of GAD 65/67 ±
SEM compared to naïve levels, whose mean was set equal to one, is shown below the images.

GABAA
Changes in expression of the GABAA receptor, a ligand-gated ion channel responsible
for the influx of chloride ions when bound to GABA, in response to GSE incubation were
investigated using immunocytochemistry (Fig. 7). In cultured trigeminal ganglia, GABAA was
detected only in the cell body of Aδ and C fiber neurons and their associated neuronal processes.
GABAA staining was not observed in satellite glia or Schwann cells. The relative intensity of
GABAA staining was not altered with GSE incubation (43.9 ± 4.8, p = 0.966, n = 6) compared to
naïve conditions (45.1 ± 3.4). A summary table of relative intensity of GABAA staining is
shown below. A callout showing representative staining of a single neuron for naïve and GSE
cultures is shown to better visualize GABAA expression. Based on immunostaining intensity
measurements, cultures incubated with GSE did not effect GABAA receptor expression in
trigeminal neurons.
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GABAB1
Immunocytochemistry was used to investigate if GSE-mediated repression of basal
CGRP secretion might correlate with changes in the expression of the GABAB1 receptor
subunit, which is responsible for ligand binding. In cultured trigeminal ganglia, GABAB1 was
abundantly expressed in the cell body and processes of Aδ and C fiber neurons (Fig. 8). Low
level GABAB1 staining was observed in the cell bodies of satellite glia and Schwann cells. The
intensity of GABAB1 staining was significantly increased in both neurons and glia in response to
GSE incubation when compared to naïve conditions. A callout of a single GABAB1 stained
neuron is shown to highlight the difference in staining intensity between the naïve and GSE
conditions. A separate callout of a few glial cells is shown for naïve and GSE conditions to
better visualize the increased GABAB1 expression in the cellular processes. Based on
immunostaining intensity measurements, GSE incubated cells showed a significant increase of
GABAB1 staining intensity in the neurons (65.2 ± 5.9, p = 0.013, n = 7) compared to naïve
control levels (43.1 ± 3.4). Similarly, a significant increase in GABAB1 staining intensity was
observed in the cell body and processes of satellite glial and Schwann cells in response to
overnight GSE incubation (20.5 ± 1.0, p = 0.006, n = 6) when compared to naïve control levels
(14.5 ± 1.4).

GABAB2
Changes in expression of the GABAB2 receptor, which is responsible for the G proteincoupling and functional expression at the cell surface, in response to GSE incubation were
investigated using immunocytochemistry. In cultured trigeminal ganglia, GABAB2 was readily
detected in neurons and glial cell bodies (Fig. 9). Staining for GABAB2 showed no intensity
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change with GSE incubation (52.0 ± 2.6, p = 0.628, n = 6) in the neurons compared to naïve
levels (50.0 ± 3.0). However, the intensity of GABAB2 immunostaining was significantly
increased in satellite glia and Schwann cells in response to GSE (11.7 ± 1.0, p = 0.016, n = 6)
when compared to levels in the naïve condition (7.3 ± 0.5). A callout of a single GABAB2
stained neuron is shown for naïve and GSE conditions to emphasize that there was no change in
staining intensity in either neuronal cell type. A separate callout of a few glial cells is shown for
both conditions to clearly demonstrate the upregulation of GABAB2 expression in the cytoplasm
and processes of each glial cell type. Based on average relative immunostaining intensity
measurements, GSE incubated cells did not exhibit a significant change in staining intensity in
the neurons, in contrast to results seen for GABAB1. However, GSE enhanced GABAB2
expression in satellite glia and Schwann cells, a finding in agreement with the GSE-mediated
increase in GABAB1 in these cells.
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Table 2. Summary of Cell Viability After GSE Incubation
Sample

Absorbance

Fold Change

Naïve

0.425

1.000

GSE 24 hr

0.488

1.146

10% DMSO 24 hr

0.290

0.648
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Schwann
Cell
Aδ Fiber
Neuron
Satellite
Glia

C Fiber
Neuron
Schwann
Cell

Aδ Fiber
Neuron

Satellite
Glia

C Fiber
Neuron
Neurons: 14%

Aδ fiber: 2%

C fiber: 12%
Glia: 86%

Satellite glia: 59%

Schwann cells: 27%

Fig. 2. Characterization of Cell Types in Primary Cultures. A representative light microscopy
image at 200x with labeled cell types (left). A representative image of DAPI stained primary
cultures imaged at 200x with labeled cell types (right). The relative abundance of each cell type
as a percentage of the total cell population is summarized in the table.
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DAPI

β-Tubulin

Merged

DAPI

CGRP

Merged

β-Tubulin

CGRP

Merged

Fig. 3. Expression of Neuronal Biomarkers in Primary Cultures. All representative images are
at 200x magnification, with a horizontal arrow indicating a C fiber neuron and a vertical arrow
indicating an Aδ fiber neuron. DAPI and β-tubulin costaining in C fiber and Aδ fiber neuronal
cell bodies and processes (top row). DAPI and CGRP costaining in C fiber and Aδ fiber
neuronal cell bodies (middle row). β-tubulin and CGRP costaining showing that only a
subpopulation of neurons abundantly express CGRP.
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Fig. 4. GSE Repression of Basal CGRP Secretion from Trigeminal Ganglion
Neurons. The amount of CGRP secreted into the culture media under unstimulated
basal condition and following 60-minute incubation with GSE was determined by
radioimmunoassay. Data is reported as pg CGRP normalized to total protein level in
the well. * = p < 0.05, n = 6 done in duplicate for each condition.
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CGRP

Merged

Condition

Naïve

GSE

GSE

Naïve

DAPI

Neurons

1.00

0.05

1.05

0.04

Fig. 5. CGRP Immunostaining Levels in Primary Cultures Does Not Change with GSE
Incubation. All representative images are at 200x magnification. DAPI, CGRP, and merged
staining of naïve (top) and GSE (bottom) conditions. White arrows indicate neuronal cell
bodies abundantly expressing CGRP. A summary table of average relative intensity ±
standard error of the mean is shown below. n = 6 done in triplicate for each condition.
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DAPI

Merged

GSE

Naïve

GAD 65/67

Aδ Fiber Neuron

C Fiber Neuron
Naive

Naive

GSE

Naïve

GSE

GSE

Neurons
1.00

0.06

1.24

0.07*

Fig. 6. GAD 65/67 Immunostaining Levels in Primary Cultures Increases in Neurons with
GSE Incubation. All representative images are at 200x magnification. DAPI, GAD 65/67,
and merged staining of naïve (top) and GSE (bottom) conditions. Callouts are shown for both
neuronal cell types, C fiber and Aδ fiber. A summary table of average relative intensity ±
standard error of the mean is shown below. * = p < 0.05; n = 9 done in triplicate for each
condition.
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GABAA

Merged

GSE

Naïve

DAPI

Aδ Fiber Neuron

C Fiber Neuron
Naive

Naive

GSE

Naïve

GSE

GSE

Neurons
1.00

0.08

0.97

0.11

Fig. 7. GABAA Immunostaining Levels in Primary Cultures Shows No Change in
Neurons with GSE Incubation. All representative images are at 200x
magnification. DAPI, GABAA, and merged staining of naïve (top) and GSE (bottom)
conditions. Callouts are shown below for both neuronal cell types, C fiber and Aδ fiber. A
summary table of average relative intensity ± standard error of the mean is shown below. n
= 6 done in triplicate for each condition.
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GABAB1

Merged

GSE

Naïve

DAPI

Aδ Fiber Neuron

C Fiber Neuron
Naive

GSE

Schwann Cell

Satellite Glial Cell

Naive

Condition

GSE

Naive

GSE

GSE

Naive

Naïve

GSE

Neurons

1.00

0.08

1.51

0.09*

Glia

1.00

0.10

1.42

0.05**

Fig. 8. GABAB1 Immunostaining Levels in Primary Cultures Increases in
Neurons and Glia with GSE Incubation. All representative images are at 200x
magnification. DAPI, GABAB1, and merged staining of naïve (top) and GSE
(bottom) conditions. Neuron and glia callouts are shown for each of the four cell
types. A summary table of average relative intensity ± standard error of the mean
is shown below. * = p < 0.05; ** = p < 0.01; n = 7 for neurons, n = 6 for glia done
in triplicate for each condition.
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Naïve (n=6)
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Fig. 9. GABAB2 Immunostaining Levels in Primary Cultures Increases in Glia,
No Change in Neurons with GSE Incubation. All representative images are at 200x
magnification. DAPI, GABAB2, and merged staining shown for naïve (top) and
GSE (bottom) conditions. Neuron and glia callouts are shown for each of the four
cell types. A summary table of average relative intensity ± standard error of the
mean is shown below. * = p < 0.05; n = 6 done in triplicate for each condition.
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DISCUSSION

Results from my study show that incubation of primary trigeminal ganglion cultures with a
proanthocyanin-enriched Healthy Origins MegaNatural® BP-Grape Seed Extract solution at a
final concentration of 0.5 ng/µL for 60 minutes significantly inhibited basal CGRP secretion.
However, CGRP expression within the neuronal cell body of Aδ and C fiber neurons as assessed
by immunocytochemistry remained unaffected even with overnight GSE incubation. This
concentration of GSE did not affect cell viability, indicating that the decrease in CGRP secretion
was not due to leakage of cytoplasmic contents because of cell death. These data demonstrate
that while this concentration of GSE is sufficient to repress basal CGRP release from neurons, it
is not sufficient to cause a decrease in overall CGRP levels following an overnight incubation.
This finding may not be surprising given that CGRP is the most abundant neuropeptide
expressed in trigeminal ganglion neurons and thus longer incubation times and higher GSE
concentrations may be required to see a corresponding change in protein levels via repression of
mRNA synthesis [52]. Alternatively, GSE may only function at the level of secretion to
decrease the effects of CGRP. The ability of GSE to inhibit constitutive secretion of CGRP from
cultured trigeminal ganglion neurons is novel. Results from prior studies with the anti-migraine
agents sumatriptan [34], topiramate [33], botulinum toxin type A [29], and a cocoa extract [1]
did not suppress basal CGRP secretion from trigeminal neurons, but only inhibited stimulated
CGRP release. Hence, GSE appears to function in a unique way to modulate the excitability
state of trigeminal neurons by suppressing constitutive CGRP secretion.
The demonstration that GSE inhibits basal CGRP release from trigeminal ganglion neurons
has important implications since CGRP is known to promote peripheral sensitization of
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nociceptive neurons via an increase in proinflammatory cytokines and stimulation of nitric oxide
release [28; 62]. Furthermore, my findings support the notion that GSE may be beneficial as a
nutraceutical since CGRP release from trigeminal neurons is implicated in prevalent orofacial
pain diseases, including migraine and TMD. Suppression of basal CGRP secretion could offer a
promising alternative or adjunctive therapeutic by countering the pro-inflammatory and
nociceptive effects of CGRP. My in vitro findings agree with prior results from our lab that had
shown GSE works in vivo to successfully inhibit the development of central sensitization and
chronic orofacial pain signaling in preclinical models of TMD and migraine [18; 21; 24; 101]. In
those studies, dietary inclusion of GSE (0.5% w/v in the drinking water), which was sufficient to
inhibit trigeminal nociception, was found to mediate its inhibitory effects via activation of the
descending inhibitory pain modulation pathway. GSE functioned by activating serotonergic,
GABAergic, and endocannabinoid receptors expressed on neurons and glial cells in the upper
spinal cord. Taken together, I propose that GSE inhibits development of peripheral and central
sensitization of the trigeminal system via suppression of CGRP signaling, which is implicated in
migraine and TMD pathology. Based on my initial results and our lab’s prior findings on GSE, I
wanted to test the hypothesis that GSE repression of CGRP secretion from primary neurons is
mediated via increased synthesis of GABA and activation of GABA receptors.
In support of my hypothesis, I found that overnight incubation of trigeminal cultures with
GSE caused a significant increase in the neuronal expression of GAD 65 and GAD 67, which are
enzymes that mediate production of the inhibitory neurotransmitter GABA [56]. Under basal,
unstimulated conditions, GAD 65/67 immunostaining was readily detected in both Aδ and C
fiber neurons and hence, these cells would function as the primary source of endogenous GABA
production and release in the primary cultures. While GAD 67 is the isoform responsible for
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basal or constitutive synthesis of GABA in the cytoplasm of the cell body, GAD 65 is a plasma
membrane anchored protein that synthesizes GABA for loading into synaptic vesicles and its
release under stimulatory conditions [12]. The secretion of GABA from trigeminal neurons
would be expected to exert an inhibitory effect on the excitability state of trigeminal ganglion
neurons and glial cells expressing GABA receptors. My finding that only trigeminal neurons
express GAD 65 and GAD 67 under basal conditions is in agreement with prior studies that
reported that trigeminal neurons, but not glial cells, express GAD 65 and GAD 67 mRNA [49]
and that GAD 65 and GAD 67 are colocalized with CGRP [68]. To my knowledge, this is the
first evidence of a polyphenolic-enriched extract promoting increased expression of GABA
producing enzymes in neuronal cells.
GSE also stimulated expression of the GABAB1 receptor subunit, which is responsible
for binding GABA and then forming a functional complex with the GABAB2 subunit [38]. The
GABAB1 receptor subunit was significantly upregulated in trigeminal ganglion Aδ and C fiber
neurons incubated overnight with GSE. However, the level of expression of the GABAB2
receptor subunit, which couples to the inhibitory G protein, remained unchanged in both types of
neurons in response to GSE. The release of CGRP from trigeminal neurons can be caused via
activation of the stimulatory G protein-PKA-cAMP coupled pathway, and this pathway is
implicated in the development of peripheral sensitization [17; 22]. Thus, the GSE-mediated
increase in the functional expression of the GABAB receptor via upregulation of GABAB1 in
trigeminal neurons could directly counter the cellular effects of other stimulatory agents such as
nitric oxide and cytokines that facilitate CGRP release [10; 33]. This change in neuronal
receptor expression would allow for more GABA binding, which could partially explain some of
the inhibitory effects of GSE observed in preclinical orofacial pain models [18; 21; 24; 101].
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Increased activation of the GABAB receptors would promote potassium efflux, inhibition of
calcium influx, and a decrease in cyclic AMP levels in the neurons, resulting in a lower neuronal
excitability state. Hence, a greater inflammatory stimulus would be required to cause
depolarization and activation of the Aδ and C fiber neurons. Additionally, GABAB receptor
activation is reported to promote glial cells to uptake extracellular potassium, which would
further promote a decrease neuronal excitability (see section below). Through these inhibitory G
protein-coupled mechanisms, activation of the GABAB receptors would lead to a lower
excitability state of the neuron and a quieting of the trigeminal system. Furthermore, these GSEmediated cellular events on the GABAergic system would be expected to inhibit the release of
neurotransmitters and neuropeptides such as CGRP from primary trigeminal neurons as
discovered in my study.
I next wanted to investigate the neuronal expression of other GABAergic proteins such as
the GABAA receptor in response to GSE. Binding of GABA to the GABAA receptor, which
functions to inhibit neuronal activation, couples to the movement of negatively charged chloride
ions across the plasma membrane to cause hypopolarization of neurons [3; 63]. Somewhat
surprisingly, GSE incubation overnight did not cause a significant change in GABAA expression
as assessed by immunocytochemistry. This finding provides evidence that the inhibitory effects
of GSE are being mediated primarily via upregulation of the GAD 65 and GAD 67 enzymes, and
the GABAB1 receptor subunit in trigeminal neurons. Interestingly, activation of the GABAA
receptor, but not GABAB, was found to play an important role in the anti-nociceptive effect of
non-invasive vagus nerve stimulation (nVNS) in a preclinical chronic migraine model [23].
Thus, it appears that the inhibitory effect of GSE and nVNS in the trigeminal system function via
activation of different GABA receptors. These findings support the notion that there may be an
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enhanced therapeutic benefit of using them together in the management of migraine and TMD.
Hence, GSE appears to be exerting its beneficial effects only through the GAD 65 and GAD 67
enzymes and the metabotropic G protein coupled GABAB receptor of trigeminal neurons. While
neurons are a critical cell type involved in inflammation and nociception, it is now appreciated
that glial cells play an important role in modulating the excitability state of neurons and the
development of peripheral sensitization [62]. For this reason, I next looked at the expression of
GABAB receptors in glial cells, since GABAB is the only GABA receptor reported to be
expressed in glia [91; 92; 99].
In my study, I found that GSE induced a significant increase in the expression of the
GABAB1 and GABAB2 receptor subunits in the cell body and processes of satellite glia in our
primary trigeminal ganglion cultures. Given the important role of glial cells in modulating the
excitability state of primary sensory neurons, this finding may offer a novel strategy for targeting
peripheral glial cells to suppress or possibly even reverse development of peripheral
sensitization. Prolonged sensitization of trigeminal neurons is known to involve CGRP and
enhanced neuron-glial cell communication via paracrine signaling and the formation of gap
junctions [28]. For example, prior studies from our lab have shown that CGRP stimulates nitric
oxide synthesis and release from trigeminal ganglion glial cells and promotes release of many
proinflammatory cytokines, such as TNF-α, that stimulate neurons to release even more CGRP
[58; 97]. Thus, inhibiting CGRP-mediated cellular events in glial cells would suppress the
development and maintenance of the neuron-glia inflammatory loop within the ganglion.
Increasing the GABAergic response in satellite glial cells would be expected to suppress
peripheral sensitization and activation of trigeminal neurons and the formation of gap junctions

44

between the neuronal cell body and satellite glial cells, which is implicated in the transition from
acute to chronic pain [31; 43].
Similarly, GSE promoted upregulation of GABAB1 and GABAB2 receptor subunits in
the cell body and processes of Schwann cells, which were recently implicated in the underlying
pathology of migraine [26]. In that study, CGRP binding to its receptor on Schwann cells led to
the production of nitric oxide and modulation of ligand-gated ion channels on Aδ and C fiber
neurons to cause cellular changes associated with allodynic pain signaling. Based on my
findings, I propose that upregulation of the GABAB receptor subunits in Schwann cells would
inhibit the synthesis and release of nitric oxide, which is stimulated by CGRP. To our
knowledge, this is the first evidence of a nutraceutical modulating GABAB subunit receptor
expression in peripheral glial cells.
Previous in vivo inhibitor studies from our lab support the idea that treatment with the
nutraceutical GSE acts to decrease orofacial pain via activation of the GABAergic system within
the upper spinal cord [24]. Thus, GSE would mediate suppression of central sensitization and
inhibit nociceptive signaling via the secondary neurons to the thalamus. However, it is known
that GABA receptors are also expressed on the processes of the trigeminal primary neurons that
project into the dorsal medullary horn of the spinal trigeminal nucleus in the upper spinal cord.
My data supports the notion that GSE’s inhibitory effect on pain signaling likely also involves
upregulation of the GABA producing enzymes GAD 65 and GAD 67 and activation of GABAB1
expression on primary trigeminal neurons (Fig. 10). Upregulation of the GAD enzymes in both
Aδ and C fiber neurons would provide an increased endogenous source of GABA both in the
trigeminal ganglion and spinal cord. This increased production of GABA would directly lead to
decreased CGRP secretion in nearby neurons by activating their GABAA and GABAB
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receptors, thus establishing a negative feedback loop involving modulation of both neurons and
glia to restore and maintain homeostasis. Further, GSE-mediated upregulation of the GABAB1
receptor subunit in neurons would inhibit CGRP secretion. In addition, upregulation of
GABAB1 and GABAB2 subunits in both satellite glia and Schwann cells would suppress the
stimulatory effects of CGRP that promote and sustain the inflammatory loop implicated in
migraine and TMD pathology. In summary, I propose that the inhibitory effects of GSE on pain
signaling in preclinical models of migraine and TMD involves modulation of GABAergic system
to suppress the development of peripheral and central sensitization of trigeminal neurons. To my
knowledge, these are novel findings that support the neuroprotective role of GSE and the
potential health benefit of using GSE as a complementary or adjunctive approach for the clinical
management of migraine and TMD and possibly other types of orofacial pain.
Findings from our lab have previously shown that dietary inclusion of GSE functions to
enhance descending inhibitory pain signaling in preclinical models of migraine and TMD via
activation of serotonergic, GABAergic, and endocannabinoid receptors to suppress central
sensitization [24; 101]. The cellular effects of GSE include upregulation of basal levels of the
enzyme MKP-1, which inactivates the pro-inflammatory MAP kinases, and the glutamate
transport proteins GLAST and GLT-1 to lower the extracellular concentrations of this
stimulatory neurotransmitter [18]. My results extend our knowledge of how GSE functions as a
neuroprotectant to suppress peripheral sensitization of trigeminal neurons via inhibition of CGRP
secretion, promotion of neuronal expression of GAD 65 and GAD 67, and enhanced GABAB
receptor expression in neurons and glia. If GSE functions similarly in humans, then inclusion of
this nutraceutical as a daily supplement would likely enhance the therapeutic benefit of currently
used drugs. GSE may enhance the effect of the GABAB agonist Baclofen, which is the only
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clinically available drug that targets the GABAB receptor [38]. Combining a nutraceutical with
a pharmaceutical, such as baclofen, could offer a more effective treatment strategy. Findings
from my study provide evidence that GSE can act peripherally to exert effects centrally. A
current preventative treatment for chronic migraine is to use a monoclonal antibody directed
against CGRP or its receptor to inhibit its downstream pro-inflammatory effects on neuron and
glial cells [95]. Since CGRP monoclonal antibodies cannot effectively cross the blood brain
barrier, this is another therapeutic in which its disease modifying effects may be improved by
inclusion of GSE as a dietary supplement. Based on findings from my study, inclusion of GSE
would function in neurons along with associated satellite glia, and nearby Schwann cells within
the trigeminal system to suppress the nociceptive effects of CGRP. Given that elevated levels of
CGRP are implicated in TMD pathology, it is highly likely that GSE would be clinically
beneficial in this orofacial pain condition that is frequently comorbid with migraine [19].
The results of my study raise many interesting questions with respect to how GSE is
functioning. Clearly, further investigations are needed to more fully understand the diverse
cellular and molecular changes mediated by GSE. Continuing my in vitro studies, I would like
to utilize immunocytochemistry using antibodies specific for the GAD 65 and GAD 67 enzymes
to determine if both proteins are being upregulated in response to GSE. Alternatively, I could
perform western blot analysis to determine changes in protein expression of the membrane
bound GAD 65 and cytosolic GAD 67 enzymes. Also using immunocytochemistry, I would like
to look at expression levels of GLAST and GLT-1 to see if GSE upregulates these proteins
peripherally as well as centrally. It would be interesting to identify which class of polyphenols
was most responsible for the inhibitory activity of GSE. I could fractionate GSE using different
solvents to isolate specific components and then evaluate those compounds in primary trigeminal
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cultures. If given the opportunity, I would like to use fluorescent microscopy to investigate GSE
mediated changes in intracellular ion levels under basal, stimulated, and GSE conditions. For
example, cells could be loaded with specific molecules that allow for quantification of ion levels
of calcium, potassium, sodium, and chloride, which would provide novel information about how
GSE specifically modulates the excitability state of neurons and glial cells. Another way to
investigate further the mechanism of action of GSE in vitro would be to perform transient
transfection of the primary cultures with different reporter plasmids to determine if GSE
inhibited promoter activity of genes known to be stimulated by CGRP, such as PKA and MAP
kinases. Results from these studies would provide evidence if GSE is suppressing the
downstream effects of CGRP at the transcriptional level. Additionally, a logical next step would
be to utilize our in vivo preclinical models of migraine and TMD and immunohistochemistry to
study the modulatory effects of GSE on the expression of GAD 65, GAD 67, and GABAB
receptor subunits in the trigeminal ganglion and upper spinal cord.
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with proteins being upregulated by GSE shown in green. See text for more details.
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